AFT Pharmaceuticals (NZX: AFT, ASX: AFP) has reported record revenue for the 12 months ending March 2023 and declared a maiden dividend of 1.1 cents per share.
Operating revenue was up 20% to $156.6 million, while operating profit from product sales and royalties rose 38% to $18.8 million.
Net profit after tax was $10.7 million, down from the $19.8 million in the same period a year ago.
The core Australasian business contributed the most to growth, with revenue increasing 23.5%.
Revenue from international product sales and royalties increased by 71%.
AFT has launched 22 new products across seven therapeutic areas and has 61 countries selling its Maxigesic dose forms.
The company has also acquired two new projects for its development portfolio and is targeting a near-term rolling twelve-month stretch revenue target of $200 million.
See more
